Detalhe da pesquisa
1.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat
; 201(3): 409-415, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37480384
2.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat
; 202(3): 485-496, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676450
3.
Opioid prescriptions at the point of surgery, bone metastasis, or death among patients with breast cancer in Japanese acute care hospitals: a claims-based, retrospective, longitudinal study.
Support Care Cancer
; 31(6): 369, 2023 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37266722
4.
Vimentin-positive invasive breast carcinoma of no special type: A breast carcinoma with lethal biological characteristics.
Pathol Int
; 73(9): 413-433, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37378453
5.
A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.
Cancer
; 128(8): 1692-1698, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045185
6.
Difference of compliance rates for the recommendations in Japanese Guideline on Febrile Neutropenia according to respondents' attributes: the second report on a questionnaire survey among hematology-oncology physicians and surgeons.
Support Care Cancer
; 30(5): 4327-4336, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35094140
7.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(1): 74-84, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387497
8.
A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology-oncology physicians and surgeons.
Support Care Cancer
; 29(11): 6831-6839, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34008079
9.
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
Int J Clin Oncol
; 26(1): 1-17, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33161452
10.
[Clinical Outcomes of Five Cases of Occult Breast Cancer in Which the Primary Site Was Not Detected in the Breast-by-Breast MRI].
Gan To Kagaku Ryoho
; 48(9): 1127-1131, 2021 Sep.
Artigo
em Japonês
| MEDLINE | ID: mdl-34521790
11.
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Cancer Sci
; 111(9): 3313-3326, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619077
12.
A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Oncologist
; 25(2): e373-e380, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043774
13.
[Patient with Recurrent Breast Cancer Who Developed Radiation Esophagitis with Severe Esophageal Stenosis after Combined Bevacizumab and Paclitaxel Therapy-A Case Report].
Gan To Kagaku Ryoho
; 47(11): 1605-1608, 2020 Nov.
Artigo
em Japonês
| MEDLINE | ID: mdl-33268737
14.
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Cancer
; 125(22): 4076-4083, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31381152
15.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Br J Cancer
; 120(5): 475-480, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30745582
16.
A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.
Jpn J Clin Oncol
; 49(2): 121-129, 2019 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30576544
17.
[The Version 2.0 Practice Guideline for Anti-Emetic and Standard Therapy].
Gan To Kagaku Ryoho
; 46(11): 1683-1685, 2019 Nov.
Artigo
em Japonês
| MEDLINE | ID: mdl-31748472
18.
Correction to: Intracellular hypoxia measured by F-18 fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen-receptor positive breast (BRCR-D17-00693).
Breast Cancer Res
; 20(1): 107, 2018 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30185224
19.
Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer.
Breast Cancer Res
; 20(1): 78, 2018 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30053906
20.
Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Future Oncol
; 14(19): 1909-1919, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29482364